LUNG
Ph
III Doce or Alimta +/- Erbitux 2Ln NSCLC
Randomized
Phase III Study of Docetaxel or Pemetrexed
with or without Cetuximab in Patients with
Recurrent or Progressive Non-Small Cell Lung
Cancer after Platinum-Based Therapy (IMCL CP02-0452).
Ph
III Talab+Doc v Plcbo+Doc 2nd3rdLn NSCLC
A
Phase III, Randomized, Double-Blind, Multicenter
Study of Talabostat and Docetaxel versus Docetaxel
and Placebo in Patients with Advanced (Stage
IIIB/IV) Non-Small Cell Lung Cancer (NSCLC)
after Failure of Platinum-Based Chemotherapy
(PTH-304).
Ph
II Alimta+C +/- Enz v Doce+C AdvNSCLC
A
Randomized, Open-Label Phase II Study of Pemetrexed
(Alimta) plus Carboplatin with or without Enzastaurin
Hydrochloride, or Docetaxel plus Carboplatin
as First Line Treatment in Patients with Advanced
Stage Non-Small Cell Lung Cancer (NSCLC).
Ph
III Talab+Alim v Plcbo+Alim NSCLC PostPt
A
Phase III, Randomized, Double-Blind, Multicenter
Study of Talabostat and Pemetrexed versus Pemetrexed
and Placebo in Patients with Advanced (Stage
IIIB/IV) Non-Small Cell Lung Cancer (NSCLC)
after Failure of Platinum-Based Chemotherapy
(PTH-305).
Amrubicin
2nd Line Refractory ED-SCLC
A
Phase II Trial of Single-Agent Amrubicin in
Patients with Extensive Disease Small Cell
Lung Cancer that is Refractory or Progressive
within 90 Days of Completion of First-Line
Platinum-based Chemotherapy.
Ph
II Amrub v Topotec 2ln SCLC; Sen 1ln
A
Randomized Phase II Trial Comparing Amrubicin
versus Topotecan as Second-Line Treatment in
Patients with Extensive Small Cell Lung Cancer
Sensitive to First-Line Chemotherapy (CNF3140-SCLC-05004).
Tarceva
Adjuv NSCLC Pts and EGFR+tumor
A
Multi-center Randomized, Double-blind, Placebo-controlled,
Phase III Study of Single-agent Tarceva (erlotinib)
Following Complete Tumor Resection with or
without Adjuvant Chemotherapy in Patients with
Stage IB-IIIA Non-small Cell Lung Carcinoma
who have EGFR-Positive Tumors.
Protocol
AVF3671g
A Randomized,
Double-blind,Placebo-controlled, Phase IIIb Trial Comparing
Bevacizumab therapy with or without Erlotinib after completion
of chemotherapy with Bevacizuman for the first-line treatment
of locally advanced, recurrent, or metastatic NSCLC.
|
l